Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations
Sally L George, Elisa Izquierdo, James Campbell, et al.
Nature Medicine
|
April 3, 2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 18, 2025
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Elizabeth R Tucker, Irene Jiménez, Lindi Chen, et al.
JCO Precision Oncology
|
October 20, 2022
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study
Olivia Ruhen, Nathalie S M Lak, Janine Stutterheim, et al.
Nature Communications
|
September 17, 2025
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Shivendra Singh, Jie Fang, Hongjian Jin, et al.
Brain : a Journal of Neurology
|
March 1, 2018
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition
Veronica Ferrucci, Pasqualino de Antonellis, Francesco Paolo Pennino, et al.
Nature Communications
|
May 3, 2024
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations
Ingrid M Saldana-Guerrero, Luis F Montano-Gutierrez, Katy Boswell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
Lucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Nature Communications
|
August 5, 2025
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function
Marta Barisa, Henrike P Muller, Elisa Zappa, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
September 24, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations
Sally L George, Elisa Izquierdo, James Campbell, et al.
Nature Medicine
|
April 3, 2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 18, 2025
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2023
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Elizabeth R Tucker, Irene Jiménez, Lindi Chen, et al.
JCO Precision Oncology
|
October 20, 2022
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study
Olivia Ruhen, Nathalie S M Lak, Janine Stutterheim, et al.
Nature Communications
|
September 17, 2025
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Shivendra Singh, Jie Fang, Hongjian Jin, et al.
Brain : a Journal of Neurology
|
March 1, 2018
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition
Veronica Ferrucci, Pasqualino de Antonellis, Francesco Paolo Pennino, et al.
Nature Communications
|
May 3, 2024
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations
Ingrid M Saldana-Guerrero, Luis F Montano-Gutierrez, Katy Boswell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
Lucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Nature Communications
|
August 5, 2025
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function
Marta Barisa, Henrike P Muller, Elisa Zappa, et al.
Page
of 12